201 related articles for article (PubMed ID: 20980285)
21. [Clinical benefits of anti-human IL-6 receptor antibody therapy].
Nishimoto N
Clin Calcium; 2007 Apr; 17(4):562-8. PubMed ID: 17404486
[TBL] [Abstract][Full Text] [Related]
22. [Therapeutic efficacy and the adverse effects of newly developed biological agents for rheumatoid arthritis].
Kondo H
Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):153-60. PubMed ID: 14968591
[No Abstract] [Full Text] [Related]
23. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis.
Zhang X; Peck R
Expert Rev Clin Pharmacol; 2011 Sep; 4(5):539-58. PubMed ID: 22114882
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
Ohsugi Y
Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
Burmester GR; Feist E; Kellner H; Braun J; Iking-Konert C; Rubbert-Roth A
Ann Rheum Dis; 2011 May; 70(5):755-9. PubMed ID: 21187298
[TBL] [Abstract][Full Text] [Related]
27. Tocilizumab and missed personalized medicine opportunities for patients with rheumatoid arthritis?
Littman BH
Arthritis Rheum; 2009 May; 60(5):1565-6. PubMed ID: 19404928
[No Abstract] [Full Text] [Related]
28. Tocilizumab in the treatment of adult rheumatoid arthritis.
Sanmartí R; Ruiz-Esquide V; Bastida C; Soy D
Immunotherapy; 2018 Mar; 10(6):447-464. PubMed ID: 29495891
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.
Tanaka E; Inoue E; Hoshi D; Shimizu Y; Kobayashi A; Sugimoto N; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2015 Jul; 25(4):503-13. PubMed ID: 25547018
[TBL] [Abstract][Full Text] [Related]
30. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment.
Nishida S; Hagihara K; Shima Y; Kawai M; Kuwahara Y; Arimitsu J; Hirano T; Narazaki M; Ogata A; Yoshizaki K; Kawase I; Kishimoto T; Tanaka T
Ann Rheum Dis; 2009 Jul; 68(7):1235-6. PubMed ID: 19525413
[No Abstract] [Full Text] [Related]
31. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials.
An MM; Zou Z; Shen H; Zhang JD; Cao YB; Jiang YY
Eur J Clin Pharmacol; 2010 Jan; 66(1):49-59. PubMed ID: 19936725
[TBL] [Abstract][Full Text] [Related]
32. Anti-interleukin 6: first line in rheumatoid arthritis?
Marti L; Scheinberg M
Clin Rheumatol; 2009 Aug; 28(8):877-9. PubMed ID: 19415377
[No Abstract] [Full Text] [Related]
33. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Kivitz A; Olech E; Borofsky M; Zazueta BM; Navarro-Sarabia F; Radominski SC; Merrill JT; Rowell L; Nasmyth-Miller C; Bao M; Wright S; Pope JE
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1653-61. PubMed ID: 24942540
[TBL] [Abstract][Full Text] [Related]
34. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial.
Ruscitti P; Masedu F; Alvaro S; Airò P; Battafarano N; Cantarini L; Cantatore FP; Carlino G; D'Abrosca V; Frassi M; Frediani B; Iacono D; Liakouli V; Maggio R; Mulè R; Pantano I; Prevete I; Sinigaglia L; Valenti M; Viapiana O; Cipriani P; Giacomelli R
PLoS Med; 2019 Sep; 16(9):e1002901. PubMed ID: 31513665
[TBL] [Abstract][Full Text] [Related]
35. FDA approves tocilizumab to treat rheumatoid arthritis.
Thompson CA
Am J Health Syst Pharm; 2010 Feb; 67(4):254. PubMed ID: 20133526
[No Abstract] [Full Text] [Related]
36. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis.
Koike R; Harigai M; Atsumi T; Amano K; Kawai S; Saito K; Saito T; Yamamura M; Matsubara T; Miyasaka N
Mod Rheumatol; 2009; 19(4):351-7. PubMed ID: 19590933
[TBL] [Abstract][Full Text] [Related]
37. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.
Jones G; Sebba A; Gu J; Lowenstein MB; Calvo A; Gomez-Reino JJ; Siri DA; Tomsic M; Alecock E; Woodworth T; Genovese MC
Ann Rheum Dis; 2010 Jan; 69(1):88-96. PubMed ID: 19297346
[TBL] [Abstract][Full Text] [Related]
38. Tocilizumab (Actemra) for rheumatoid arthritis.
Med Lett Drugs Ther; 2010 Jun; 52(1340):47-8. PubMed ID: 20539266
[No Abstract] [Full Text] [Related]
39. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
Emery P; Keystone E; Tony HP; Cantagrel A; van Vollenhoven R; Sanchez A; Alecock E; Lee J; Kremer J
Ann Rheum Dis; 2008 Nov; 67(11):1516-23. PubMed ID: 18625622
[TBL] [Abstract][Full Text] [Related]
40. Tocilizumab.
Venkiteshwaran A
MAbs; 2009; 1(5):432-8. PubMed ID: 20065633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
